Blocking Spinal Enzyme sPLA2 Immediately After Nerve Injury Prevents Pain and Neural Hyperexcitability | Research

The takeaway

Inhibiting spinal sPLA2 at the time of nerve root compression prevented pain, reduced neuronal hyperexcitability, and normalized inflammatory and neuropeptide gene expression in rats.

Pain prevented at day 1
Immediate sPLA2 inhibition completely prevented mechanical allodynia and normalized spinal inflammatory markers

What the researchers found

Immediate intrathecal sPLA2 inhibition after C7 nerve root compression prevented mechanical allodynia, attenuated dorsal horn hyperexcitability, restored normal neuronal classification, and reduced mGluR5, substance P, IL1α, and IL1β gene expression to sham levels.

Why it matters

Nerve root compression (as in herniated discs) causes persistent pain that is difficult to treat once established. Identifying a window for early intervention could prevent chronic pain development.

The numbers in context

Allodynia prevented at day 1; dorsal horn hyperexcitability attenuated; mGluR5, substance P, IL1α, IL1β reduced to sham levels

How the study worked

Rat model of C7 nerve root compression with immediate intrathecal administration of sPLA2 inhibitor (thioetheramide-phosphorylcholine). Three groups: injury + treatment, injury alone, sham. Assessed at day 1: behavioral sensitivity, spinal neuronal excitability via electrophysiology, and spinal gene expression for glutamate receptors/transporters, substance P, and pro-inflammatory cytokines.

Who was studied

Rats with C7 nerve root compression injury

What this study cannot tell us

Only day 1 assessed — unknown if protection persists long-term. Immediate treatment at injury time is not realistic for most clinical scenarios. Rat model may not fully replicate human cervical radiculopathy.

How to read the evidence

Preliminary — single time-point rat study with promising but very early-stage results. Clinical applicability of immediate treatment is uncertain.

When this study was published

Published in 2020; the role of sPLA2 in spinal pain processing continues to be investigated.

The bigger picture

This study supports the concept of a critical early window in neuropathic pain where intervention can prevent central sensitization — the amplification process that makes acute pain become chronic.

Questions still open

How long does the protective effect of sPLA2 inhibition last beyond day 1?
Would delayed sPLA2 inhibition (hours or days post-injury) still be effective?
Could sPLA2 inhibitors be developed for clinical use in acute nerve root injuries?

Common questions

What is sPLA2 and why does it cause pain?

Secretory phospholipase A2 is an enzyme that breaks down cell membrane fats, releasing inflammatory molecules. After nerve injury, spinal sPLA2 triggers a cascade of inflammation, glutamate signaling, and substance P release that amplifies pain signals.

Could this approach prevent chronic pain after disc herniation?

In theory, early sPLA2 inhibition could prevent the spinal sensitization that makes acute nerve compression pain become chronic. However, the treatment would need to be given very early after injury, which is a practical challenge in clinical settings.

Read the original research

Immediate inhibition of spinal secretory phospholipase A2 prevents the pain and elevated spinal neuronal hyperexcitability and neuroimmune regulatory genes that develop with nerve root compression.

Neuroreport, 31(15), 1084-1089

View on PubMed ↗Publisher’s paper ↗

Citation

Quindlen-Hotek, Julia C; Kartha, Sonia; Winkelstein, Beth A. (2020). Immediate inhibition of spinal secretory phospholipase A2 prevents the pain and elevated spinal neuronal hyperexcitability and neuroimmune regulatory genes that develop with nerve root compression.. Neuroreport, 31(15), 1084-1089. https://doi.org/10.1097/WNR.0000000000001520